Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial

医学 苏伽马德克斯 新斯的明 神经肌肉阻滞 麻醉 封锁 罗库溴铵 外科 梅德林 并发症 神经肌肉监测 临床试验
作者
Kate Leslie,Kate Leslie,Jai N. Darvall,Matthew T V Chan,Philip J. Peyton,Paul Stewart Myles,Tomas B. Corcoran,Timothy G. Short,Benjamin L Olesnicky,Ashley R. Webb,Nancy Devlin,An Tran‐Duy,Helen Maxwell-Wright,Cindy Schultz-Ferguson,Phoebe Fitzpatrick,Sofia Sidiropoulos,Sabine Braat,David A. Story,Kate Leslie,Kate Leslie
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:14 (9): 761-774 被引量:4
标识
DOI:10.1016/s2213-2600(26)00158-x
摘要

BACKGROUND: Sugammadex and neostigmine are used to reverse aminosteroid neuromuscular-blocking drugs at the end of surgery. We aimed to determine whether reversal of neuromuscular blockade with sugammadex reduces the incidence of postoperative pulmonary complications or death compared with neostigmine. METHODS: We conducted a pragmatic, international, multicentre, randomised, controlled, phase 4 trial involving 44 hospitals in Australia, Aotearoa New Zealand, and Hong Kong. Eligible patients were adults (aged ≥40 years) who were having abdominal or thoracic surgery under general anaesthesia and lasting at least 2 h, with an expected postoperative hospital stay of 1 night or longer. Patients were randomly assigned (1:1) to sugammadex or neostigmine, administered intravenously in doses chosen by the attending anaesthesiologist, for reversal of rocuronium-induced or vecuronium-induced neuromuscular blockade at the end of surgery. Randomisation was done via a web-based service, in random permuted blocks of varying sizes of 2 and 4 and stratified by centre. Patients, research staff who were responsible for outcome assessments, and members of the endpoint adjudication committee were masked to group assignment. The primary outcome was postoperative pulmonary complications or death up to hospital discharge (or postoperative day 7 if still in hospital). The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623000394640) and is closed to accrual. FINDINGS: Patients were recruited between July 21, 2023, and July 3, 2025; 3498 patients were included in the intention-to-treat population (1745 [49·9%] in the sugammadex group and 1753 [50·1%] in the neostigmine group). Postoperative pulmonary complications or death occurred in 331 (19·0%) of 1743 patients in the sugammadex group and 377 (21·5%) of 1752 patients in the neostigmine group (risk ratio [RR] 0·88 [95% CI 0·77-1·00]; p=0·049). Death occurred in one (0·1%) and two (0·1%) patients (RR 0·50 [95% CI 0·05-5·53]; p >0·99), atelectasis in 320 (18·4%) of 1742 patients and 370 (21·1%) of 1750 patients (0·86 [0·76-0·99]; p=0·030), pneumonia in 37 (2·1%) of 1742 patients and 38 (2·2%) of 1750 patients (0·98 [0·62-1·53]; p=0·92), and pulmonary aspiration in four (0·2%) of 1742 and seven (0·4%) of 1750 patients (0·57 [0·17-1·96]; p=0·38) in the sugammadex and neostigmine groups, respectively. Acute respiratory distress syndrome was not reported. No adverse events were deemed to be treatment related. INTERPRETATION: Sugammadex reduced the incidence of postoperative pulmonary complications or death compared with neostigmine. The risk reduction was small with atelectasis of uncertain clinical significance being the most common complication. Sugammadex can be considered as a first-line drug for reversal of aminosteroid-induced neuromuscular blockade at the end of surgery. FUNDING: Australian Medical Research Future Fund and the Hong Kong Health and Medical Research Fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
帅气一凤完成签到,获得积分10
刚刚
葫萝北发布了新的文献求助10
1秒前
04d的应助被ddl采纳,获得10
1秒前
王一二完成签到 ,获得积分10
1秒前
1秒前
两仪完成签到 ,获得积分10
1秒前
1秒前
陶醉山灵发布了新的文献求助10
1秒前
Qin完成签到,获得积分20
1秒前
2秒前
wanci的应助被tt采纳,获得10
2秒前
仁爱之双完成签到,获得积分10
2秒前
moanthy发布了新的文献求助10
2秒前
2秒前
刘灿完成签到,获得积分10
2秒前
2秒前
凯kai发布了新的文献求助10
3秒前
3秒前
3秒前
狗大王完成签到,获得积分10
3秒前
土多多完成签到,获得积分10
3秒前
liu完成签到,获得积分10
4秒前
桐桐的应助被刘小孩采纳,获得20
4秒前
qiqi发布了新的文献求助10
4秒前
5秒前
小鱼完成签到,获得积分10
5秒前
6秒前
6秒前
典雅秋白完成签到,获得积分10
6秒前
Qin发布了新的文献求助10
6秒前
蒙蒙完成签到,获得积分10
7秒前
陶醉山灵完成签到,获得积分10
7秒前
He完成签到 ,获得积分10
7秒前
尼古丁真的应助被周浩宇采纳,获得10
7秒前
8秒前
糖淘淘发布了新的文献求助10
8秒前
帕提麦完成签到,获得积分10
8秒前
Rxin发布了新的文献求助10
8秒前
肖李完成签到,获得积分20
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153389
求助须知:如何正确求助?哪些是违规求助? 9550014
关于积分的说明 21696271
捐赠科研通 7741851
什么是DOI,文献DOI怎么找? 3425440
关于科研通互助平台的介绍 2550608
邀请新用户注册赠送积分活动 2469123